Vischer advised Chinese companies Kelun-Biotech and Harbour BioMed in all Swiss law matters of a licencing agreement. Moreover, the Swiss law firm assisted RTW, an investor, within the seed financing round of Winward Bio, the
Tags :Matthias Staehelin
Vischer advised Ikerian, a healthcare software platform company, on its first round of USD 8m Series B financing to advance its AI platform. The Series B financing round is led by strategic investor Sanoptis led
Vischer advised Mininavident, located in Liestal, a developer and manufacturer of the world’s smallest dynamic navigation system for dental implant placement, which was acquired by the Straumann Group, a global leader in tooth replacement,
Oculis Holding has completed a financing of approximately $59m, consisting of the issuance of 5,000,000 of its ordinary shares at a purchase price of $11.75 per share. A prospectus required for the listing on the Nasdaq Iceland
The Swiss dental startup Odne has raised USD 5.5m to fund the upcoming US market launch for their minimal invasive Root Preservation Technology (RPT). The Series A1 round for Odne, was led by Revere Partners (
GlycoEra AG in Wädenswil, has increased its Series A Financing Round with a substantial additional investment by Bristol Meyer Squibb (BMS) to further support the development of its innovative platform to enable high-throughput design
Proteomedix, a Swiss private, commercial-stage diagnostics oncology company and Water Biotech are forming together a company called Onconetix. The transaction is implemented by the acquisition of Proteomedix for an all stock consideration. Onconetix’s commercial
Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, has announced the completion of its oversubscribed Series C equity financing raising EUR 67.5m (USD 72m) from a syndicate
Memo Therapeutics, a late-stage biotech company developing best-in-class therapeutic antibodies closed a CHF 25 million series C financing round led by Pureos Bioventures. Existing investors Swisscanto, Vesalius Biocapital, Adjuvant Capital, Verve Ventures, Schroders Capital, GF Group,
Vischer acted as legal advisor to LimmaTech Biologics as it successfully concluded a USD 37 million (CHF 33 million) Series A financing round, co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund.